STOCKHOLM (Reuters) Mar 11 – Swedish biotech firm Artimplant expects EU approval soon for a biodegradable implant to treat arthritis of the thumb.
The product, called a spacer, is implanted at the base of the thumb. Over time, new functioning tissue evolves as the spacer degrades and then disappears. "It is not that far away. I think we could have [EU approval] at the end of the year or early next year," Artimplant Chief Executive Anders Cedronius told Reuters.
Artimplant already has European approval to market biodegradable knee implants for repairing torn ligaments, and expects to apply to the US Food and Drug Administration (FDA) for approval in the second or third quarter of this year.
An application with the FDA will be filed for the thumb implant when further studies have finished. "We have high hopes they will look favourably on an application since this is a method that really adds something to existing treatments," Cedronius said.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!